Regeneron's weight-loss drug combo helps preserve muscle in study
The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, according to interim data from the 599-patient study.
The results mark an early win for Regeneron as it races against a dozen companies to develop obesity treatments that preserve muscle, as they seek to find the next breakthrough in the potential $150 billion weight-loss drug market.
Blockbuster weight-loss drugs from Novo Nordisk and Eli Lily (LLY.N), opens new tab have helped patients shed fat, but also led to muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients.
Wegovy helped patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy led to weight loss of about 21.6 pounds, with only 3.7 pounds in lean mass.
"While we wait for detailed data, we believe that these data give a glimpse into the potential for these drugs to preserve muscle," said Truist analyst Srikripa Devarakonda.
Meanwhile, a triple combination of Novo's semaglutide, Regeneron's trevogrumab and experimental antibody garetosmab led to a substantially higher rate of discontinuation due to tolerability issues and other side effects, Regeneron said.
The full data set will be available later this year, the drugmaker said.
Regeneron on Monday announced a licensing deal worth up to $2.01 billion with China's Hansoh Pharmaceuticals (3692.HK), opens new tab for an experimental obesity drug.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
16 minutes ago
- Reuters
Venture Global's Plaquemines LNG export facility drives profit beat
Aug 12 (Reuters) - Liquefied natural gas exporter Venture Global (VG.N), opens new tab on Tuesday beat Wall Street expectations for second-quarter core profit, as higher production from its Plaquemines LNG export facility in Louisiana boosted sales. Venture Global is the U.S.' second-largest LNG exporter, and has been responsible for most of the growth in the country's LNG exports since 2023, according to the U.S. Energy Information Administration. It has also helped the U.S. remain the world's largest exporter of the superchilled gas. The Arlington, Virginia-based company said its 27.2-million-metric-ton Plaquemines facility was operating at 77% of its capacity, with 28 of its 36 plants - also called trains - now producing LNG. Shares of the company rose 4%. The company reported adjusted EBITDA of $1.39 billion for the three months ended June 30, compared with analysts' expectations of $1.25 billion. Plaquemines generated operating income of $921 million, Venture Global said in an earnings filing. Its quarterly revenue of $3.1 billion exceeded analysts' expectations of $2.89 billion, according to data compiled by LSEG, driven mainly by the start of the Plaquemines project. The company sold 329 trillion British Thermal Units (TBtu) of LNG during the second quarter, a 149% jump from the 132 TBtu of LNG it sold a year earlier. Venture Global expects to export 227 to 240 cargos of LNG from Plaquemines this year. Its Calcasieu Pass export facility in Louisiana, which started operations in 2023, is expected to export 144 to 149 cargos this year. The company anticipates changes in fixed liquefaction fees to reduce its annual adjusted earnings before interest, taxes, depreciation, and amortization by $230 million to $240 million, compared with expectations of a $460 million to $480 million impact previously. The results could drive outperformance in Venture Global's stock, especially given it has fallen nearly 50% since the company went public in January, RBC Capital Markets analyst Elvira Scotto said. Venture Global, which is locked in contract arbitration disputes with several global energy majors, including BP (BP.L), opens new tab, Shell (SHEL.L), opens new tab, Repsol ( opens new tab, Edison ( opens new tab, Orlen ( opens new tab and Galp ( opens new tab, said a decision in one of the proceedings is expected "imminently." The companies have accused Venture Global of delaying the commercial startup of its Calcasieu Pass plant from 2023 to 2025 to benefit from higher spot market prices rather than what it would have earned under long-term contracts. With Venture Global facing several lawsuits related to its long commissioning of the Calcasieu Pass facility, the first ruling could set precedent for the remaining proceedings, according to J.P. Morgan analyst Jeremy Tonet. Venture Global estimates a penalty of up to $1.6 billion if it loses the arbitration cases, according to Tuesday's earnings report. Some of the companies involved in the arbitration are pushing for a higher penalty, the report said. The company reported a decline of $449 million in earnings from its Calcasieu Pass operations, compared to the same period in 2024, driven by lower earnings due to sales of LNG on long-term contracts and not on the spot market, the filing showed.
The Independent
16 minutes ago
- The Independent
Star Trek actor reveals more details about Quentin Tarantino's abandoned film
Simon Pegg revealed that Quentin Tarantino 's unmade Star Trek film would have been "bats*** crazy," fitting expectations for a Tarantino project. Pegg, who portrays Montgomery "Scotty" Scott, was given a detailed description of the R-rated script by JJ Abrams and producer Lindsey Weber, though he never read it. Tarantino successfully pitched the film in 2017 but later distanced himself from the project, which was never officially greenlit. Pegg previously indicated that the Star Trek film franchise might be over due to high production costs and lower box office returns compared to other major franchises. However, Pegg now expresses hope for another film following the merger between Paramount and Skydance, as Skydance founder David Ellison supports the Kelvin timeline.
BBC News
17 minutes ago
- BBC News
Musk threatens Apple and calls OpenAI boss a liar as feud deepens
X owner Elon Musk has threatened Apple with legal action after claiming it had made it "impossible" for apps to compete with ChatGPT-maker OpenAI in its App called OpenAI boss Sam Altman a "liar" - after Altman claimed Musk used his platform to "benefit himself and his own companies".The row is the latest flashpoint in what is an ongoing feud between the billionaires who co-founded OpenAI - but now fiercely compete after Musk left the announced a partnership with ChatGPT in June 2024 - but there is no suggestion Apple favours one app over the other, and several rival AI apps such as DeepSeek and Perplexity have topped the App Store charts since then. The BBC has approached Apple for a later post Musk took aim at Apple again, asking the firm why it would not promote X - or its AI app Grok - in the "Must Have" section of the App Store."X is the #1 news app in the world and Grok is #5 among all apps," he said in a post now pinned to his X is currently the most downloaded free app in the UK, with Grok a close third. X does not make the top seemed to draw the attention of Altman, who linked to a report by tech newsletter Platformer which claimed Musk had made his own personal X posts more prominent in people's feeds. Bad blood The feud between Musk and Altman has, over time, encompassed a slew of lawsuits, email dumps and social media rivalry can be traced back a decade, with Musk's now public belief that OpenAI, under Altman's leadership, abandoned the principles he and others used to found it in firm was created with the intention of building artificial general intelligence (AGI) - AI that can perform any task that a human being is capable of - but by making its technology open-source and promising to "benefit humanity".What is AI and how does it work?OpenAI was also set up as a not-for-profit company, meaning it would not aim to make money, but in 2019 it established a for-profit arm which Musk felt was antithetical to its original argued in his March 2024 lawsuit that the firm had instead been focusing on "maximising profits" for its major investor while he unexpectedly dropped his lawsuit last year, OpenAI then filed a counter-suit against him in claimed the X owner had engaged "non-stop" in "bad-faith tactics" to try and slow down the company's AI has also claimed Musk is not motivated by preserving the company's founding mission - but rather by his "own agenda".And the feud has not stopped at just words and legal action. In February, Musk made a shock move to try and buy the company for $100bn (£74bn) - a bid rejected by OpenAI's board.
